Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by PeriRx
Sponsor:
Information provided by (Responsible Party):
PeriRx
ClinicalTrials.gov Identifier:
NCT01587573
First received: April 26, 2012
Last updated: April 22, 2016
Last verified: April 2016
  Purpose
The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions suspicious for cancer.

Condition Intervention
Oral Squamous Cell Carcinoma
Other: saliva collection prior to clinically driven oral biopsy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma

Resource links provided by NLM:


Further study details as provided by PeriRx:

Primary Outcome Measures:
  • Test specificity at 90% sensitivity [ Time Frame: at study completion as well as after model development following enrollment of the first 30 patents with cancer ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Validation of individual mRNA and protein markers [ Time Frame: After enrollment of 30 patients with cancer ] [ Designated as safety issue: No ]
  • Validation of a pre-specified multi marker model [ Time Frame: After enrollment of 30 patients with cancer ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
cell free saliva

Estimated Enrollment: 370
Study Start Date: April 2012
Estimated Study Completion Date: November 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
oral lesions
oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
Other: saliva collection prior to clinically driven oral biopsy
cell free saliva to be used to measure mRNA and proteins by PCR and ELISA

Detailed Description:
Saliva samples are collected from patients before clinically driven oral biopsy for lesions suspicious for cancer. Specimens are processed by laboratory personnel blinded to the tissue diagnosis. Six pre-specified mRNA markers (IL1b, IL8, SAT, DUSP1, OAZ1 and S100P) are measured by polymerase chain reaction. Markers are compared in cancer and control by raw Ct values as well as by delta Ct after adjustment for housekeeping gens. Appropriate housekeeping genes are identified in a random subset of cancer and control patients and then verified in the remaining subjects. Predictive models are generated by a pre-specified method and robustness evaluated by bootstrap analysis. The model is then further validated in a second cohort. Three pre-specified protein markers (IL8, IL1B, and M2BP) are a secondary endpoint and will also be compared in cancer and control patients.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with oral lesions suspicious for squamous cell cancer and scheduled for clinically driven biopsy
Criteria

Inclusion Criteria:

  • Adult patients scheduled for biopsy of an oral lesion suspicious for squamous cell cancer

Exclusion Criteria:

  • Patients with known prior oral malignancy in last 2 years or other cancer in last 5 years other than non melanoma skin cancer or with immune deficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01587573

Locations
United States, Illinois
University of Illinois at Chicago Withdrawn
Chicago, Illinois, United States, 60612
United States, Michigan
University of Michigan Terminated
Ann Arbor, Michigan, United States, 48109
Department of Surgery, Michigan Sate University Terminated
East Lansing, Michigan, United States, 48912
St. John Providence Health System Recruiting
Warren, Michigan, United States, 48092
Contact: Michael Shaw, PhD    248-967-7791    Michael.Shaw@providence-stjohnhealth.org   
Principal Investigator: Harvey Zalesin, DDS         
Principal Investigator: Paul Hoff, MD         
United States, Pennsylvania
Main Line Health System Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Marc Surkin, MD    610-446-6900      
Sponsors and Collaborators
PeriRx
Investigators
Principal Investigator: Jack L Martin, MD PeriRx, LLC
Study Chair: Marc Surkin, MD Main Line Health System
  More Information

Responsible Party: PeriRx
ClinicalTrials.gov Identifier: NCT01587573     History of Changes
Other Study ID Numbers: PeriRx-1 
Study First Received: April 26, 2012
Last Updated: April 22, 2016
Health Authority: United States: Institutional Review Board
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by PeriRx:
salivary biomarkers

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell

ClinicalTrials.gov processed this record on September 23, 2016